Suboxone vs. Vivitrol: What's the Difference and Which Works Better?

At-a-Glance Comparison: Suboxone vs. Vivitrol

Key Takeaways

• Suboxone is best for early recovery. It stops withdrawal symptoms within hours of the first dose, reduces cravings, and can be started while someone is still physically dependent on opioids.
• Vivitrol is a blocker, not a stabilizer. It contains no opioids and creates no physical dependence — but it does nothing to relieve withdrawal symptoms. You must complete a medically supervised detox before the first shot.
• The detox barrier is Vivitrol's biggest clinical limitation. The definitive head-to-head trial from the NIDA Clinical Trials Network found that only 72% of patients assigned to Vivitrol were able to start it, compared to 94% who started Suboxone. Early relapses — often occurring during the detox waiting period — were responsible for most of the outcome gap between the two medications.
• Once both are started, outcomes are similar. Among patients who successfully initiated both medications, 24-week relapse rates were statistically comparable: 52% for Vivitrol vs. 55.6% for Suboxone in the X:BOT trial. The challenge is getting to that first dose.
• Vivitrol has one unique advantage: It is FDA-approved to treat both opioid use disorder and alcohol use disorder, making it clinically relevant for people struggling with both simultaneously.
• Relapse on Vivitrol carries a higher overdose risk than relapse on Suboxone. Because Vivitrol blocks opioid receptors, tolerance decreases during treatment. If someone stops Vivitrol and uses opioids, the dose that once felt manageable may now be dangerous.

Two Completely Different Philosophies of Treatment

The fundamental difference between Suboxone and Vivitrol is not just pharmacological — it is philosophical. Understanding what each medication is trying to accomplish helps clarify which approach fits which person.

Suboxone: Stabilization

Suboxone works by partially filling opioid receptors — "quieting" the brain's demand for opioids by maintaining a consistent, low level of receptor activation. This stabilization approach has two effects: it prevents the brain from signaling withdrawal, and it blunts the reward response to other opioids. The brain is satisfied enough that the urgent need to seek opioids diminishes substantially. Patients on Suboxone describe feeling normal, not high — they can work, maintain relationships, and engage in therapy without the constant intrusion of withdrawal symptoms or cravings.

This approach acknowledges that opioid use disorder involves profound changes in brain chemistry that cannot be immediately reversed by willpower or therapy alone. The medication creates a stable foundation from which genuine recovery work can begin.

Vivitrol: Blockade

Vivitrol works by occupying opioid receptors without activating them — creating a complete chemical shield. If someone on Vivitrol uses heroin, oxycodone, or any other opioid, those drugs cannot attach to the receptors and produce their effect. The high is chemically prevented. This blockade approach does not reduce cravings by satisfying the brain's opioid demand; instead, it removes the reward that drives continued use. Over time, the hope is that repeated experiences of "nothing happens if I use" reduce the behavioral reinforcement of opioid use.

Vivitrol is most effective for people who have already stabilized biologically — who have completed detox, whose withdrawal has fully resolved, and who are primarily managing the psychological and behavioral aspects of recovery rather than acute physical dependence.

Neither approach is morally superior. They serve different patients at different stages of recovery.

Does Vivitrol Help With Withdrawal?

No. This is one of the most important and most misunderstood facts about Vivitrol.

Naltrexone — the active ingredient in Vivitrol — is an opioid antagonist. It blocks opioid receptors rather than activating them. If given to someone who is physically dependent on opioids, it immediately triggers severe precipitated withdrawal by stripping opioids from the receptors without providing any substitute activation. The resulting withdrawal is intense, rapid, and extremely uncomfortable.

For this reason, Vivitrol cannot be used to manage withdrawal at any stage. Before the first injection, patients must be completely opioid-free for at least 7 days — and clinical guidelines recommend 10–14 days to be safer, particularly for patients who were using long-acting opioids or fentanyl. During this waiting period, patients experience full, unmedicated opioid withdrawal — exactly the experience that Suboxone is designed to prevent.

This is clinically significant because it creates a dangerous vulnerability window. The 7–14 day detox period required before starting Vivitrol is the period when relapse risk is highest, and when overdose risk is elevated because opioid tolerance drops rapidly during detox. People who attempt to white-knuckle through this period without medication support face serious risks.

Suboxone, by contrast, can be started within 12–24 hours of the last opioid use — as soon as mild-to-moderate withdrawal begins.

The Detox Barrier: Why Vivitrol's Success Rate Is Complicated

This is the most important section for understanding the true clinical comparison between these two medications — and the one most often misrepresented.

The X:BOT Trial: What the Data Actually Shows

The definitive head-to-head comparison of Suboxone and Vivitrol was the X:BOT trial, published in The Lancet in 2018 and sponsored by NIDA. It enrolled 570 opioid-dependent adults at eight community treatment centers and randomized them to either monthly Vivitrol injections or daily Suboxone.

The headline finding that was widely reported: Once patients started both medications, 24-week relapse rates were similar — 52% for Vivitrol vs. 55.6% for Suboxone among those who successfully initiated treatment.

The finding that was often buried: Only 72.1% of patients assigned to Vivitrol actually started the medication, compared to 94.1% of those assigned to Suboxone. The patients who could not initiate Vivitrol — nearly 1 in 4 of those assigned to it — relapsed during the detox waiting period, before ever receiving their first dose.

The consequence for overall outcomes: When all 570 participants were analyzed together — including those who never started their assigned medication — 24-week relapse rates were 65.4% for Vivitrol versus 56.8% for Suboxone. The difference was driven almost entirely by the initiation gap.

The clinical bottom line, as stated by Dr. Sarah Wakeman of Massachusetts General Hospital: "The take-home from this study is that buprenorphine is more effective than Vivitrol" — not because the medications perform differently once started, but because significantly more patients can actually start buprenorphine.

What Happens If You Relapse on Vivitrol?

This is a critical safety distinction that patients considering Vivitrol need to understand clearly.

While taking Vivitrol, opioid receptors are blocked — which means using opioids produces no effect. But during the weeks of Vivitrol treatment, opioid tolerance drops significantly. The brain no longer needs to maintain the elevated tolerance that developed during active opioid use.

If a patient stops Vivitrol — or if the monthly injection wears off — and then uses opioids, their tolerance is much lower than it was before treatment. A dose of heroin or oxycodone that they previously used regularly can now produce respiratory depression or overdose at a fraction of the former amount. This is a well-documented pattern with opioid antagonist treatments and is one of the most important reasons that discontinuing Vivitrol without a transition plan and close clinical support carries real danger.

Suboxone's partial receptor occupation means that opioids have reduced effect during treatment — and if relapse occurs, the brain's baseline state is maintained by buprenorphine, providing some buffer against overdose.

Switching from Suboxone to Vivitrol: What It Takes

Many people on Suboxone eventually consider transitioning to Vivitrol — often because they want to be on a non-opioid medication or have concerns about physical dependence on buprenorphine.

The transition requires the same medically supervised detox period required for first-time Vivitrol patients. Buprenorphine must be fully cleared from the system before the first naltrexone injection. Because buprenorphine has a long half-life (24–42 hours), and because it binds so tightly to opioid receptors, full clearance typically takes longer than detox from short-acting opioids — often 7–14 days of abstinence, and sometimes longer.

Transition protocol:

• Taper buprenorphine dose gradually under physician supervision — abrupt discontinuation causes significant withdrawal
• Allow 7–14 days of complete opioid abstinence after the last buprenorphine dose
• Confirm absence of physical withdrawal and opioid-free status before the first Vivitrol injection
• Receive first 380 mg intramuscular injection, followed by monthly injections thereafter

This transition is medically manageable but requires planning, support, and close physician oversight. Attempting it without guidance significantly increases the risk of relapse during the clearance period.

Side Effects: What's Different Between the Two

Both medications share some overlapping side effects — nausea, headache, fatigue, and insomnia are reported with both. The key differences come from their delivery methods and mechanisms.

Suboxone: Oral Health Risk

As described in FDA safety communications issued in 2022, transmucosal buprenorphine — including Suboxone films and tablets — is associated with dental problems including tooth decay, cavities, oral infections, and in some cases tooth loss. The sublingual film lowers oral pH each time it dissolves, creating an acidic environment that can erode enamel over time.

FDA-recommended oral care with Suboxone:

• After the film or tablet fully dissolves, swish a large sip of water around the mouth
• Swallow the water
• Wait at least one hour before brushing teeth
• Maintain regular dental checkups

Vivitrol: Injection Site Reactions

Vivitrol is administered as a deep intramuscular injection into the gluteal muscle — not subcutaneous, like Brixadi or Sublocade. This means the injection goes deeper and uses a larger needle. Injection site reactions are the most commonly reported side effects:

• Pain at the injection site (very common)
• Tenderness, induration, or bruising (common)
• A firm nodule or lump at the site (expected — resolves over weeks)
• Rare but serious: injection site necrosis — tissue damage requiring medical attention, particularly if the injection is too shallow (subcutaneous rather than intramuscular)

Patients should report unusual or worsening injection site symptoms to their provider promptly.

Vivitrol's Hepatotoxicity Warning

Naltrexone carries a boxed warning about the risk of hepatocellular injury at high doses. At the doses used in Vivitrol (380 mg monthly), this risk is generally low in patients without preexisting liver disease, but liver function should be monitored. Patients with acute hepatitis or liver failure should not receive Vivitrol.

Side Effect Comparison

Who Is the Ideal Candidate for Each?

Choose Suboxone If:

• You are currently in active withdrawal and need relief now
• You are not yet ready or able to complete a 7–14 day medically supervised detox
• You have high, persistent cravings that need direct pharmacological management
• You prefer telehealth and at-home care
• You have previously tried Vivitrol and found the waiting period too difficult
• Your primary substance is opioids (not alcohol)
• You are early in recovery and your dose may need frequent adjustment

Choose Vivitrol If:

• You have already completed a full medically supervised detox and are at least 7–10 days opioid-free
• You also struggle with alcohol use disorder — Vivitrol is FDA-approved for both
• You prefer a non-opioid, non-scheduled medication with no physical dependence
• You have philosophical or personal objections to taking an opioid-derived medication
• You have a stable recovery foundation and primarily need relapse prevention rather than withdrawal management
• You are in a criminal justice, employment, or professional licensing context where opioid-containing medications face scrutiny

Pros and Cons: Suboxone vs. Vivitrol

Suboxone (Buprenorphine/Naloxone)

Pros:

• Immediately relieves withdrawal — can start within 12–24 hours of last opioid use
• Strong craving reduction
• Significantly lower detox barrier — 94% of patients in the X:BOT trial started successfully
• Telehealth accessible — Bicycle Health serves patients in 30+ states
• Covered by most major insurance plans including Medicaid
• Ceiling effect limits overdose risk
• Generic available at $50–$200/month

Cons:

• Creates physical dependence — requires a taper to discontinue
• Daily dosing (though injectable options like Sublocade exist)
• Dental health risk from sublingual film
• Contains an opioid — faces stigma in some settings
• Schedule III controlled substance

Vivitrol (Extended-Release Naltrexone)

Pros:

• No opioid content — no physical dependence, no controlled substance designation
• Once-monthly injection — no daily medication management
• FDA-approved for both OUD and alcohol use disorder
• Opioid blockade: relapse produces no rewarding effect
• Can be stopped at any time without taper
• Fewer drug interactions than buprenorphine or methadone

Cons:

• Requires complete 7–14 day detox before first dose — highest risk period
• Does not treat withdrawal symptoms at any stage
• Only 72% of opioid-dependent patients in the X:BOT trial could successfully initiate it
• Significant overdose risk if discontinued and opioids are used (tolerance loss)
• ~$1,000–$1,500 per injection — substantially more expensive than generic Suboxone
• Injection site reactions, including rare necrosis
• Hepatotoxicity boxed warning — liver monitoring required
• Injection requires in-person visit

Frequently Asked Questions

Does Vivitrol help with withdrawal?

No. Vivitrol (naltrexone) is an opioid antagonist — it blocks opioid receptors rather than activating them. Taking Vivitrol while opioids are still in the system causes precipitated withdrawal, an intense, sudden withdrawal reaction. Vivitrol cannot be used to manage or relieve withdrawal symptoms at any point in treatment. The 7–14 day opioid-free period required before the first injection is when withdrawal must be managed through other means, such as medical supervision, comfort medications (clonidine, anti-nausea medications), and supportive care.

What are the success rates of Vivitrol vs. Suboxone?

The X:BOT trial — the definitive NIDA-sponsored head-to-head study — found that among all 570 participants, 24-week relapse rates were 65.4% for Vivitrol and 56.8% for Suboxone. Among the 474 patients who successfully started both medications, relapse rates were statistically similar: 52% for Vivitrol and 55.6% for Suboxone. The overall gap is driven by the fact that only 72% of Vivitrol-assigned patients could successfully initiate it, compared to 94% of those assigned to Suboxone. If a patient can complete the detox period and start Vivitrol, outcomes are comparable. The clinical challenge is getting there.

Is it safe to switch from Suboxone to Vivitrol?

Yes, but it requires careful medical management. Buprenorphine must be fully cleared from the system before the first Vivitrol injection — which typically means 7–14 days of complete abstinence after tapering off Suboxone. Your physician should supervise the taper, help manage withdrawal during the clearance period, and confirm opioid-free status before the injection is given.

Can I take Vivitrol if I drink alcohol?

Yes — in fact, this is one of Vivitrol's clinical advantages. It is FDA-approved for both alcohol use disorder and opioid use disorder. The same naltrexone mechanism that blocks opioid reward also reduces alcohol craving and the pleasurable effects of drinking. For patients who struggle with both alcohol and opioids simultaneously, Vivitrol addresses both conditions with a single medication. Suboxone has no approved indication for alcohol use disorder.

What happens if I miss a Vivitrol injection?

If a Vivitrol injection is missed or delayed, opioid receptor blockade begins to diminish, creating a window during which opioid use could produce an effect — and during which opioid tolerance remains suppressed relative to baseline. If you miss a scheduled injection, contact your provider as soon as possible to reschedule. Do not attempt to use opioids during this period — your tolerance is lower than you may realize, and the risk of overdose is elevated.

Can I get Vivitrol through telehealth?

The evaluation, prescription, and coordination for Vivitrol can involve telehealth — but the injection itself must be administered in person by a healthcare provider. Unlike Suboxone, which can be managed entirely through telehealth and picked up at a standard pharmacy, Vivitrol requires a certified provider for the intramuscular injection. Bicycle Health can help coordinate Suboxone treatment entirely through telehealth.